126 related articles for article (PubMed ID: 12361396)
1. Imidazole inhibitors of cytokine release: probing substituents in the 2 position.
Laufer SA; Striegel HG; Wagner GK
J Med Chem; 2002 Oct; 45(21):4695-705. PubMed ID: 12361396
[TBL] [Abstract][Full Text] [Related]
2. From imidazoles to pyrimidines: new inhibitors of cytokine release.
Laufer SA; Wagner GK
J Med Chem; 2002 Jun; 45(13):2733-40. PubMed ID: 12061876
[TBL] [Abstract][Full Text] [Related]
3. Novel substituted pyridinyl imidazoles as potent anticytokine agents with low activity against hepatic cytochrome P450 enzymes.
Laufer SA; Wagner GK; Kotschenreuther DA; Albrecht W
J Med Chem; 2003 Jul; 46(15):3230-44. PubMed ID: 12852754
[TBL] [Abstract][Full Text] [Related]
4. Tetrasubstituted imidazole inhibitors of cytokine release: probing substituents in the N-1 position.
Laufer SA; Zimmermann W; Ruff KJ
J Med Chem; 2004 Dec; 47(25):6311-25. PubMed ID: 15566301
[TBL] [Abstract][Full Text] [Related]
5. An in-vitro screening assay for the detection of inhibitors of proinflammatory cytokine synthesis: a useful tool for the development of new antiarthritic and disease modifying drugs.
Laufer S; Greim C; Bertsche T
Osteoarthritis Cartilage; 2002 Dec; 10(12):961-7. PubMed ID: 12464556
[TBL] [Abstract][Full Text] [Related]
6. Quantitative structure-activity relationship study of benzylsulfanyl imidazoles as cytokine release inhibitors.
Singh P; Sharma BK
J Enzyme Inhib Med Chem; 2007 Feb; 22(1):15-21. PubMed ID: 17373542
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and structure-activity relationship of aminobenzophenones. A novel class of p38 MAP kinase inhibitors with high antiinflammatory activity.
Ottosen ER; Sørensen MD; Björkling F; Skak-Nielsen T; Fjording MS; Aaes H; Binderup L
J Med Chem; 2003 Dec; 46(26):5651-62. PubMed ID: 14667219
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis and anti-inflammatory activity of imidazol-5-yl pyridine derivatives as p38α/MAPK14 inhibitor.
Ali EMH; Abdel-Maksoud MS; Hassan RM; Mersal KI; Ammar UM; Se-In C; He-Soo H; Kim HK; Lee A; Lee KT; Oh CH
Bioorg Med Chem; 2021 Feb; 31():115969. PubMed ID: 33422910
[TBL] [Abstract][Full Text] [Related]
9. RWJ 67657, a potent, orally active inhibitor of p38 mitogen-activated protein kinase.
Wadsworth SA; Cavender DE; Beers SA; Lalan P; Schafer PH; Malloy EA; Wu W; Fahmy B; Olini GC; Davis JE; Pellegrino-Gensey JL; Wachter MP; Siekierka JJ
J Pharmacol Exp Ther; 1999 Nov; 291(2):680-7. PubMed ID: 10525088
[TBL] [Abstract][Full Text] [Related]
10. Role of MAP kinase pathways in mediating IL-6 production in human primary mesangial and proximal tubular cells.
Leonard M; Ryan MP; Watson AJ; Schramek H; Healy E
Kidney Int; 1999 Oct; 56(4):1366-77. PubMed ID: 10504489
[TBL] [Abstract][Full Text] [Related]
11. A critical role for p38 mitogen-activated protein kinase in the maturation of human blood-derived dendritic cells induced by lipopolysaccharide, TNF-alpha, and contact sensitizers.
Arrighi JF; Rebsamen M; Rousset F; Kindler V; Hauser C
J Immunol; 2001 Mar; 166(6):3837-45. PubMed ID: 11238627
[TBL] [Abstract][Full Text] [Related]
12. Imidazopyrimidines, potent inhibitors of p38 MAP kinase.
Rupert KC; Henry JR; Dodd JH; Wadsworth SA; Cavender DE; Olini GC; Fahmy B; Siekierka JJ
Bioorg Med Chem Lett; 2003 Feb; 13(3):347-50. PubMed ID: 12565927
[TBL] [Abstract][Full Text] [Related]
13. MKK3/6-p38 MAPK signaling is required for IL-1beta and TNF-alpha-induced RANKL expression in bone marrow stromal cells.
Rossa C; Ehmann K; Liu M; Patil C; Kirkwood KL
J Interferon Cytokine Res; 2006 Oct; 26(10):719-29. PubMed ID: 17032166
[TBL] [Abstract][Full Text] [Related]
14. Monocyte intracellular cytokine production during human endotoxaemia with or without a second in vitro LPS challenge: effect of RWJ-67657, a p38 MAP-kinase inhibitor, on LPS-hyporesponsiveness.
Faas MM; Moes H; Fijen JW; Muller Kobold AC; Tulleken JE; Zijlstra JG
Clin Exp Immunol; 2002 Feb; 127(2):337-43. PubMed ID: 11876759
[TBL] [Abstract][Full Text] [Related]
15. Small molecular anti-cytokine agents.
Wagner G; Laufer S
Med Res Rev; 2006 Jan; 26(1):1-62. PubMed ID: 16283677
[TBL] [Abstract][Full Text] [Related]
16. Inhibitors of mitogen-activated protein kinases differentially regulate eosinophil-activating cytokine release from human airway smooth muscle.
Hallsworth MP; Moir LM; Lai D; Hirst SJ
Am J Respir Crit Care Med; 2001 Aug; 164(4):688-97. PubMed ID: 11520738
[TBL] [Abstract][Full Text] [Related]
17. Strong inhibition of TNF-alpha production and inhibition of IL-8 and COX-2 mRNA expression in monocyte-derived macrophages by RWJ 67657, a p38 mitogen-activated protein kinase (MAPK) inhibitor.
Westra J; Doornbos-van der Meer B; de Boer P; van Leeuwen MA; van Rijswijk MH; Limburg PC
Arthritis Res Ther; 2004; 6(4):R384-92. PubMed ID: 15225374
[TBL] [Abstract][Full Text] [Related]
18. Unexpected reaction of 2-alkylsulfanylimidazoles to imidazol-2-ones: pyridinylimidazol-2-ones as novel potent p38alpha mitogen-activated protein kinase inhibitors.
Koch P; Laufer S
J Med Chem; 2010 Jun; 53(12):4798-802. PubMed ID: 20481631
[TBL] [Abstract][Full Text] [Related]
19. The MAP kinase inhibitors, PD098059, UO126 and SB203580, inhibit IL-1beta-dependent PGE(2) release via mechanistically distinct processes.
Newton R; Cambridge L; Hart LA; Stevens DA; Lindsay MA; Barnes PJ
Br J Pharmacol; 2000 Jul; 130(6):1353-61. PubMed ID: 10903976
[TBL] [Abstract][Full Text] [Related]
20. Design and synthesis of potent, selective, and orally bioavailable tetrasubstituted imidazole inhibitors of p38 mitogen-activated protein kinase.
Liverton NJ; Butcher JW; Claiborne CF; Claremon DA; Libby BE; Nguyen KT; Pitzenberger SM; Selnick HG; Smith GR; Tebben A; Vacca JP; Varga SL; Agarwal L; Dancheck K; Forsyth AJ; Fletcher DS; Frantz B; Hanlon WA; Harper CF; Hofsess SJ; Kostura M; Lin J; Luell S; O'Neill EA; O'Keefe SJ
J Med Chem; 1999 Jun; 42(12):2180-90. PubMed ID: 10377223
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
